Live Breaking News & Updates on Kalbe Genexine Biologics
Stay updated with breaking news from Kalbe genexine biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
General Atlantic to invest $55 million in Indonesiaâs Kalbe Farma biotech JV By Syndicated Content Jan 26, 2021 11:10 PM SINGAPORE (Reuters) - Global private equity firm General Atlantic will invest $55 million in Kalbe Genexine Biologics (KGBio), a joint venture of Indonesian pharmaceuticals firm PT Kalbe Farma and South Korean biotech firm Genexine Inc. The investment will go towards KGBio s ongoing clinical development and help boost its production capacity, among others, the companies said in a joint statement on Wednesday. As a global player in life sciences, General Atlantic brings an extensive network and deep expertise in innovation that KGBio aims to leverage, said Sie Djohan, director of Kalbe Farma and chief exectuive officer of KGBio. ....
Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17 Kalbe Gets Phase-2 Clinical Trial Approval on COVID-19 Drug - GX17 Jakarta, 30 December 2020 - PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe-Genexine Biologics (KGBio) today has received approval for a clinical trial (PPUK) from the Food and Drug Administration of the Republic of Indonesia (BPOM) to carry out Phase 2 clinical trials of the drug GX-17, which is an immunotherapeutic drug that will be developed as a treatment for COVID-19 patients. BPOM has issued approval to KGBio to conduct a phase-2 clinical trial based on safety and effectiveness data from a previous study conducted by Genexine with IMAB in South Korea. GX-17 is the only long-acting interleukin-7 drug under development in the world that can increase the absolute lymphocyte count. This increase in the number of lymphocytes by GX-17 can prevent the worsening of the condition of mild or asymptomatic COVID-19 patients, especially ....